Taylor 1976.

Methods	Study design: parallel RCT Study duration: not reported Study follow‐up: 12 months RCT Multicentre ‐ 12 centres across Canada 12 month follow up
Participants	Country: Canada Setting: multicentre (12) Inclusion criteria: DD kidney transplant recipients Number: treatment group (87); control group (92) Mean age ± SD (years): not reported Sex (M/F): not reported Exclusion criteria: ABO incompatibility; positive direct crossmatch; previous ALG therapy; positive skin test for sensitivity to horse serum protein; previous transplant
Interventions	Treatment group Horse ALG: 20 mg/kg IV over 8 h once/d for 10 days, starting post‐op (some via CVC, some via AVF) Control group No ALG Immunosuppression (both groups) As per treating physician, could include: AZA PRED/hydrocortisone Actinomycin D Graft radiation 'Dose adjusted according to progress'
Outcomes	Death Graft loss Acute rejection Other complications
Notes	Funding source: Medical Research Council, Canada
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Table of random numbers used
Allocation concealment (selection bias)	Low risk	sealed envelopes with patient allocations, only opened during operation
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Unlikely to influence outcomes
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement, in particular, not clear how acute rejection episodes were diagnosed and what made them a minor versus a major acute rejection episode
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patient outcome data reported
Selective reporting (reporting bias)	High risk	All expected outcomes reported; graft function reported at 60 days but not able to be used in analyses of this review as no SD or SE given
Other bias	Low risk	Appears free of other bias; funding by Medical Research Council, Canada